A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual ki
- This topic has 0 replies, 1 voice, and was last updated 7 years, 7 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel.
https://www.ncbi.nlm.nih.gov/pubmed/27963619
Viewing 1 post (of 1 total)
- The forum ‘Clinical Trials’ is closed to new topics and replies.